Welcome to our dedicated page for ALNA news (Ticker: ALNA), a resource for investors and traders seeking the latest updates and insights on ALNA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ALNA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ALNA's position in the market.
Allena Pharmaceuticals (NASDAQ: ALNA) announced positive clinical results for ALLN-346, an oral enzyme targeting hyperuricemia in gout and chronic kidney disease (CKD). In a Phase 1 trial involving 24 healthy volunteers, ALLN-346 was well-tolerated without significant safety issues. The enzyme operates effectively in the gastrointestinal tract, which may reduce the burden on the kidneys. Allena plans to advance to Phase 1b and Phase 2 studies in 2021 to further investigate ALLN-346's efficacy and safety.
Allena Pharmaceuticals (NASDAQ: ALNA) announced that its President and CEO, Louis Brenner, M.D., will participate in a virtual fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020, at 1:25 p.m. ET. A live audio webcast will be accessible in the 'Events and Presentations' section on the company's website, with a replay available for 30 days post-presentation.
Allena specializes in developing oral enzyme therapeutics for rare metabolic and kidney disorders, with lead candidate reloxaliase undergoing a pivotal Phase 3 trial for enteric hyperoxaluria.
Allena Pharmaceuticals (NASDAQ:ALNA) reported third quarter 2020 financial results, highlighting a net loss of $8.0 million, a reduction from $13.3 million in Q3 2019. Cash and equivalents stood at $30.1 million. Allena completed dosing in its Phase 1 trial of ALLN-346 and is actively enrolling patients in URIROX-2, its pivotal trial for reloxaliase in enteric hyperoxaluria (EH). The company entered a $25 million financing agreement with Pontifax, extending its cash runway into Q4 2021.
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) announced participation in three investor conferences in November, focusing on their innovative oral enzyme therapeutics for metabolic and kidney disorders. The events include the 29th Annual Credit Suisse Virtual Healthcare Conference on November 10 at 1:15 p.m. ET, the H.C. Wainwright & Co. 6th Annual Israel Conference on November 12 at 11:00 a.m. ET, and the Jefferies Virtual London Healthcare Conference from November 17-19, with one-on-one meetings available. Live audio webcasts can be accessed on their website.
Allena Pharmaceuticals (NASDAQ:ALNA) announced the appointment of Dr. Ann Miller to its board of directors, bringing extensive experience in launching blockbuster therapies. Dr. Miller’s expertise will support Allena as it advances its Phase 3 URIROX program for reloxaliase, aimed at treating enteric hyperoxaluria. Her previous roles include leadership positions at Sanofi, Eisai, and Amgen. Additionally, founding board member Dr. Bob Tepper has resigned, marking a significant leadership change. This transition may influence Allena's strategic direction and efforts to build a patient-focused commercial organization.
Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) has secured a $25 million convertible debt financing agreement with Pontifax Medison Finance. This financing will extend Allena’s cash runway into Q4 2021, enabling the development of their oral enzyme therapeutics targeting rare metabolic disorders. The first tranche of $10 million has been accessed, with future tranches pending conditions. Pontifax can convert the debt into equity at $4.10 per share. The announcement underscores Allena's commitment to advancing its clinical programs, notably reloxaliase and ALLN-346, aimed at severe kidney disorders.
Allena Pharmaceuticals (NASDAQ: ALNA) announced participation in two investor conferences this September. Management will take part in the Baird 2020 Global Healthcare Conference on September 10 at 9:40 a.m. ET and the H.C. Wainwright & Co. 22nd Annual Global Investor Conference on September 15 at 12:30 p.m. ET. Live audio webcasts for both events will be accessible on the company’s website, with replays available for 30 days post-presentation. Allena focuses on developing first-in-class oral enzyme therapeutics for rare metabolic and kidney disorders, notably its lead candidate, reloxaliase.
Allena Pharmaceuticals (NASDAQ: ALNA) announced that President and CEO Louis Brenner will present a corporate overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020, at 8:35 a.m. ET. A live audio webcast will be accessible in the Investors section of the company’s website, with a replay available for 30 days after the event. Allena specializes in developing oral enzyme therapeutics for rare metabolic and kidney disorders, focusing on hyperoxaluria treatment with its lead product candidate, reloxaliase.
Allena Pharmaceuticals (NASDAQ: ALNA) announced an increased public offering of 5,125,384 shares at $1.30 each, due to strong demand. The offering, managed by H.C. Wainwright & Co., is expected to close around July 30, 2020, pending customary conditions. The gross proceeds are estimated at $6.7 million before deductions, with funds aimed at working capital. Additionally, the underwriter has a 30-day option for 768,807 more shares. Allena focuses on developing oral enzyme therapeutics for severe metabolic and kidney disorders, highlighted by its lead candidate, reloxaliase.
Allena Pharmaceuticals (ALNA) announced an underwriting agreement with H.C. Wainwright to sell 3,846,154 shares at $1.30 each, aiming for gross proceeds of approximately $5 million. The closing of the offering is expected around July 30, 2020, pending customary conditions. Additionally, H.C. Wainwright has a 30-day option to purchase 576,923 more shares. Proceeds are intended for working capital and corporate needs. The offering is registered under Form S-3. Allena focuses on developing treatments for severe metabolic and kidney disorders, specifically its lead candidate reloxaliase for hyperoxaluria.
FAQ
What is the market cap of ALNA (ALNA)?
